Genmab Reports Strong Q1 2025 Financial Results and Product Approvals

Genmab ( (GMAB) ) has provided an update.

On May 8, 2025, Genmab released its financial results for the first quarter of 2025, highlighting significant achievements and financial growth. The company reported a 19% increase in revenue compared to the same period in 2024, reaching $715 million, driven by higher royalties from DARZALEX® and Kesimpta®. Key developments included the approval of EPKINLY® for an additional indication in Japan and Tivdak® in Japan and the EU for cervical cancer treatment. These advancements underscore Genmab’s commitment to expanding its product reach and enhancing its position in the oncology market.

Spark’s Take on GMAB Stock

According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.

Genmab’s overall stock score reflects its strong financial performance and optimistic earnings call, highlighting revenue and profit growth and strategic investments. The valuation suggests potential undervaluation, while technical analysis indicates moderate strength. Key risks include dependency on major products and competitive pressures.

To see Spark’s full report on GMAB stock, click here.

More about Genmab

Genmab A/S is a biotechnology company based in Denmark, primarily focused on the development of antibody therapeutics for the treatment of cancer. The company collaborates with major pharmaceutical firms like Johnson & Johnson and Novartis, and its market focus includes products such as DARZALEX® and Kesimpta®.

Average Trading Volume: 1,470,505

Technical Sentiment Signal: Sell

Current Market Cap: $13.01B

For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.